INNOTEST® PHOSPHO-TAU(181P)

Looking for additional resources?

Create your free e-services account and get access.
  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited acces to our free e-learning videos
  • See all event dates where our products are presented

The INNOTEST® PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF).

The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-5). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) (6-7).

Art. no. 81574 (96T – CE-IVD) - see also Art. no. 81581 (96T - RUO) - Please contact your local Fujirebio representative for the availability of this product in your country.

 

Features & Benefits             

  • User-friendly enzyme  immunoassay, standard technology
  • Generic and color-coded components
  • Easily automated on microplate processor (generic components)
  • Ready-to-use Calibrators reduce inter and intra run variation
  • Run Validation Controls for assay run validation
  • Sample volume: 75 µL CSF. Duplicate testing is strongly recommended and requires 2 x 75 µL CSF.
  • Limit of Detection: 13 pg/mL
    Calibrator range: 15,6 to 1000 pg/mL
  • This assay should be used in combination with the PHOSPHO-TAU CAL-RVC pack, article no. 81575.

 

References

  1. Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
  2. Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
  3. Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
  4. Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23
  5. Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.
  6. Vanmechelen et al. CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B. Alzheimer’s disease: Advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley & Sons; 2001. p. 285-291.
  7. De Vreese et al. Discrimination of dementia with Lewy bodies from Alzheimer’s disease via determination of the phospho-tau concentration in cerebrospinal fluid. 18th International Conference of Alzheimer’s Disease. Barcelona, Spain, October 23-26, 2002.

Additional useful information about Alzheimer’s disease can be found on the following websites:

The Alzheimer forum site:

Additional resources:

These resources are either available in free access or for users holding a Premium eServices account:

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Looking for additional resources?

Create your free eServices account and get access to all our extra documentation (certificates, data sheets, ...), event dates where our products are presented, FAQs, ...

  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited access to our free eLearning videos
  • See all event dates where our products are presented

Already have an account? Log in here

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.

Looking for additional resources?

Create your free e-services account and get access.
  • Find & download CoA, SDS and CE declarations of conformity
  • Unlimited acces to our free e-learning videos
  • See all event dates where our products are presented

Quick access